PriceTargets.com logo

Concert Pharmaceuticals - CNCE Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.37 As of 03/6/2023 01:00 AM ET
+0 (0.00%)
Get New Concert Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNCE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNCE

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Concert Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.37.

This chart shows the closing price for CNCE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Concert Pharmaceuticals. This rating has held steady since December 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/20/2023JonestradingReiterated RatingBuy ➝ Hold
1/19/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
1/19/2023JMP SecuritiesDowngradeMarket Perform
1/19/2023Truist FinancialDowngradeBuy ➝ Hold
9/13/2022Truist FinancialBoost TargetBuy$22.00 ➝ $25.00
8/24/2022JonestradingInitiated CoverageBuy$17.00
3/4/2022HC WainwrightReiterated RatingBuy$17.00
11/12/2021JMP SecuritiesLower TargetOutperform$17.00 ➝ $10.00
10/5/2021MizuhoReiterated RatingBuy$13.00 ➝ $9.00
7/2/2021HC WainwrightReiterated RatingBuy$17.00
5/4/2021MizuhoReiterated RatingBuy$13.00
2/2/2021Truist FinancialLower Target$30.00 ➝ $22.00
2/2/2021HC WainwrightReiterated RatingBuy$25.00 ➝ $17.00
12/16/2020Berenberg BankInitiated CoverageBuy$25.00
11/4/2020JMP SecuritiesInitiated CoverageOutperform
10/2/2020MizuhoReiterated RatingBuy$18.00
9/14/2020MizuhoReiterated RatingBuy$18.00
6/1/2020MizuhoReiterated RatingBuy$18.00
3/30/2020Jefferies Financial GroupInitiated CoverageBuy$23.00
2/27/2020Stifel NicolausDowngradeHold$8.00 ➝ $11.00
1/29/2020MizuhoReiterated RatingBuy$18.00
1/24/2020HC WainwrightReiterated RatingBuy$25.00
1/22/2020SunTrust BanksReiterated RatingBuy$25.00 ➝ $30.00
1/22/2020JMP SecuritiesReiterated RatingOutperform
12/3/2019SunTrust BanksBoost TargetBuy$25.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
9/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Concert Pharmaceuticals logo
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.
Read More

Today's Range

Now: $8.37
Low: $8.37
High: $8.37

50 Day Range

MA: $8.37
Low: $8.33
High: $8.40

52 Week Range

Now: $8.37
Low: $2.66
High: $8.55

Volume

N/A

Average Volume

2,970,800 shs

Market Capitalization

$401.26 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52

Frequently Asked Questions

What sell-side analysts currently cover shares of Concert Pharmaceuticals?

The following Wall Street analysts have issued stock ratings on Concert Pharmaceuticals in the last year: StockNews.com.
View the latest analyst ratings for CNCE.

What is the current price target for Concert Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Concert Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Concert Pharmaceuticals in the next year.
View the latest price targets for CNCE.

What is the current consensus analyst rating for Concert Pharmaceuticals?

Concert Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CNCE.

What other companies compete with Concert Pharmaceuticals?

Other companies that are similar to Concert Pharmaceuticals include KalVista Pharmaceuticals, Arbutus Biopharma, CytomX Therapeutics, Magenta Therapeutics and MEI Pharma. Learn More about companies similar to Concert Pharmaceuticals.

How do I contact Concert Pharmaceuticals' investor relations team?

Concert Pharmaceuticals' physical mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company's listed phone number is (781) 860-0045 and its investor relations email address is [email protected]. The official website for Concert Pharmaceuticals is www.concertpharma.com. Learn More about contacing Concert Pharmaceuticals investor relations.